{"id":{"repo_id":"debrecen","oai_identifier":"oai:dea.lib.unideb.hu:2437/273840"},"canonical_url":"https://search.dev.ndltd.org/etd/debrecen/oai:dea.lib.unideb.hu:2437/273840","repository":{"repo_id":"debrecen","name":"University of Debrecen","base_url":"https://dea.lib.unideb.hu/server/oai/request"},"display":{"title":"New advances in the chemotherapy of Glioblastoma multiforme","abstract":"Glioblastoma multiforme is a primary tumor of the Central nervous System affecting mainly the brain. It is classified by the world health organisation as a grade IV glioma. It is indeed a very deadly tumor with an average life expectancy after diagnosis of about 14 months even after surgery, chemotherapy and radiotherapy. This review analyses the most recent therapy modalities as well as the ongoing clinical trials with new therapeutic options. Other aspects of the tumor are also discussed, including the pathology and epidemiology.","abstract_html":"Glioblastoma multiforme is a primary tumor of the Central nervous System affecting mainly the brain. It is classified by the world health organisation as a grade IV glioma. It is indeed a very deadly tumor with an average life expectancy after diagnosis of about 14 months even after surgery, chemotherapy and radiotherapy. This review analyses the most recent therapy modalities as well as the ongoing clinical trials with new therapeutic options. Other aspects of the tumor are also discussed, including the pathology and epidemiology.","abstract_has_math":false,"creators":["Chiogbonda, Wisdom Chimenem"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"DE--Általános Orvostudományi Kar","school":null,"contributors":[],"advisors":["Megyeri, Attila"],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-07-27T19:13:32Z","subjects":["Glioblastoma Multiforme"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2437/273840","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Megyeri, Attila"]},{"key":"dc:contributor.department","label":"Department","values":["DE--Általános Orvostudományi Kar"]},{"key":"dc:creator","label":"Author","values":["Chiogbonda, Wisdom Chimenem"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2019-09-30T10:41:15Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2019-09-30T10:41:15Z"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Glioblastoma Multiforme"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/2437/273840"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Glioblastoma multiforme is a primary tumor of the Central nervous System affecting mainly the brain. It is classified by the world health organisation as a grade IV glioma. It is indeed a very deadly tumor with an average life expectancy after diagnosis of about 14 months even after surgery, chemotherapy and radiotherapy. This review analyses the most recent therapy modalities as well as the ongoing clinical trials with new therapeutic options. Other aspects of the tumor are also discussed, including the pathology and epidemiology."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["egységes, osztatlan"]},{"key":"dc:title","label":"Title","values":["New advances in the chemotherapy of Glioblastoma multiforme"]}]}],"canonical_facts":{"dc:contributor.advisor":["Megyeri, Attila"],"dc:contributor.department":["DE--Általános Orvostudományi Kar"],"dc:creator":["Chiogbonda, Wisdom Chimenem"],"dc:date.accessioned":["2019-09-30T10:41:15Z"],"dc:date.available":["2019-09-30T10:41:15Z"],"dc:description.abstract":["Glioblastoma multiforme is a primary tumor of the Central nervous System affecting mainly the brain. It is classified by the world health organisation as a grade IV glioma. It is indeed a very deadly tumor with an average life expectancy after diagnosis of about 14 months even after surgery, chemotherapy and radiotherapy. This review analyses the most recent therapy modalities as well as the ongoing clinical trials with new therapeutic options. Other aspects of the tumor are also discussed, including the pathology and epidemiology."],"dc:description.degree":["egységes, osztatlan"],"dc:identifier.uri":["http://hdl.handle.net/2437/273840"],"dc:language.iso":["en"],"dc:subject":["Glioblastoma Multiforme"],"dc:title":["New advances in the chemotherapy of Glioblastoma multiforme"]},"updated_at":"2026-07-27T19:13:32Z"}